Disclosed is a super fast-acting insulin composition, comprising: a therapeutically effective concentration of a fast-acting insulin analog for maintaining normal blood glucose levels, wherein the blood glucose levels are prandial blood glucose levels and a concentration of a hyaluronan degrading enzyme sufficient to render the composition a super fast-acting insulin composition upon administration, wherein the super fast-acting insulin composition has an onset of action that is faster than the analog alone, and a duration of action that is shorter than the analog alone, whereby, upon administration, the composition closely mimics the physiologic post-prandial insulin release of a non-diabetic subject to achieve glycemic control and the super fast-acting insulin composition is formulated for a route of administration selected from among subcutaneous, intradermal, intramuscular and intraperitoneal administration.
